Correction to: Effectiveness of biosimilar pegfilgrastim in patients with multiple myeloma after high‑dose melphalan and autologous stem cell transplantation
Ann Hematol. 2023 Aug;102(8):2297-2298.
doi: 10.1007/s00277-023-05323-1.
1 Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato‑Oncology and Radiotherapy, Grande Ospedale Metropolitano "Bianchi-Melacrino-Morelli,", 89124, Reggio Calabria, Italy. [email protected].
2 Stem Cell Transplant Program CIC587, 89124, Reggio Calabria, Italy. [email protected].
3 Institute of Clinical Physiology (IFC-CNR), Section of Rome, 00185, Rome, Italy.
4 Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato‑Oncology and Radiotherapy, Grande Ospedale Metropolitano "Bianchi-Melacrino-Morelli,", 89124, Reggio Calabria, Italy.
5 Stem Cell Transplant Program CIC587, 89124, Reggio Calabria, Italy.
6 Hematology Unit, Department of Hemato‑Oncology and Radiotherapy, Grande Ospedale Metropolitano "Bianch I-Melacrino-Morelli,", 89124, Reggio Calabria, Italy.
7 Pharmacy Unit, Department of Hemato‑Oncology and Radiotherapy, Grande Ospedale Metropolitano "Bianch I-Melacrino-Morelli,", 89124, Reggio Calabria, Italy.
8 Institute of Clinical Physiology (IFC-CNR), Section of Reggio Calabria, 89124, Reggio Calabria, Italy.